An RCT of Metformin Vs Orlistat in Obese Anovulatory Women
Anovulation, Obesity
About this trial
This is an interventional treatment trial for Anovulation focused on measuring Polycystic ovary syndrome, Obesity, metformin, orlistat
Eligibility Criteria
Inclusion Criteria: 1. In the childbearing period 2. Obese with a body mass index of 30 or more. 3. Are anovulatory as shown by day 21-serum progesterone. 4. Polycystic ovarian syndrome will be diagnosed according if at least two of the following three features are present, after exclusion of other aetiologies (Azziz, 2004): (i) Oligo- or anovulation, (ii) Clinical and/or biochemical hyperandrogenism (iii) Polycystic ovaries. Exclusion Criteria: BMI of less than 30 Patients not requesting treatment for their symptoms Patients with contraindications for any of the medications: renal or hepatic impairment, malabsorption syndrome, cholestasis Diabetic patients Pregnancy Breast feeding
Sites / Locations
- Sheffield Teaching Hospitals NHS Trust, Jessop Wing